Early Value Assessments are not shortcuts to reimbursement. They are tests of whether a technology deserves the NHS’s attention while uncertainty is still unresolved. In recent years, NICE has been …
#MedTech
-
-
Belgium’s DRG debate is often framed as a shift toward “case-based payment.” That description is technically correct but strategically misleading. In Belgium, DRGs are not a market-shaping instrument; they are …
-
Germany rarely announces a reimbursement change with fanfare. It tends to arrive indirectly through regulation, measurement, and administrative architecture. Sepsis is the latest example. From 1 January 2026, sepsis care …
-
Why “SaMD” Is the Wrong Place to Start On paper, Software as a Medical Device (SaMD) looks like progress.It gives artificial intelligence in healthcare a name, a definition, and a …
-
The HAS / CNEDiMTS route explained science, law, and real-world decisions France operates one of the most structured and evidence-based reimbursement systems for medical devices in Europe. Access is not …
-
MedTech / IVD VC Funding: the investor is modelling reimbursement physics, not admiring your science Most founders pitch MedTech as if capital is attracted by novelty. In regulated healthcare, the …
-
How to Use German NUB Reimbursement Without Getting Trapped After nearly two decades of operational data, one conclusion is unavoidable: German NUB reimbursement is not a neutral innovation gateway. It …
-
Introduction: How NICE Approval in the NHS Is Now Secured Securing approval from the National Institute for Health and Care Excellence (NICE) remains one of the most decisive milestones for …
-
Why SNOMED CT and dm+d changes matter fundamentally for Digital Health, MedTech, and Biotech companies Between 2025 and 2026, the NHS will quietly implement one of the most consequential digital …
-
Denmark is often described as a “DRG country”. That is technically true but strategically misleading. On the surface, the Danish DRG system looks familiar: national groupers, published tariffs, annual updates, …